Arbutus Biopharma Corporation ABUS
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · arbutusbio.com
Clinical-stage biopharmaceutical company focused on chronic hepatitis B (imdusiran, AB-101), with significant lipid-nanoparticle patent licensing and enforcement economics through Genevant. British Columbia-incorporated, headquartered in Warminster, Pennsylvania.
Key ratios
FreeCashFlowOnSale 2025 -2.81
FreeCashFlowOnSale 2024 -10.54
FreeCashFlowOnSale 2023 -4.79
NetIncomeMargin TTM 0.84
NetIncomeMargin 2025 -2.38
ReturnOnAssets TTM 0.49
ReturnOnAssets 2025 -0.15
ReturnOnAssets 2024 -0.32
ReturnOnAssets 2023 -0.29
ReturnOnEquity TTM 0.95
ReturnOnEquity 2025 -0.39
ReturnOnEquity 2024 -0.69
ReturnOnEquity 2023 -0.6
TotalRevenueYoYGrowth 2025 1.28
TotalRevenueYoYGrowth 2024 -0.66
TotalRevenueYoYGrowth 2023 -0.54